Drug Trial Radar · NCT05434234
A Study of YL201 in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jun 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
312
Planned (sponsor's estimate)
Start
May 25, 2022
Primary completion
Apr 6, 2027
Study completion Oct 6, 2027
Sponsor
- Lead sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 27, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 1, multicenter, nonrandomized, open-label, first-in-human study of YL201 conducted in China and the United States. The study will include 2 parts: a dose escalation part (Part 1) followed by a dose expansion part (Part 2). Part 1 will estimate the MTD/RED(s) in dose escalation cohorts of patients with advanced solid tumors unresponsive to currently available therapies or for whom no standard therapy is available. Part 2 will include patients with selected advanced solid tumor types enrolled at the MTD/RED(s), to better define the safety profile and evaluate the efficacy of YL201.
Conditions
- Advanced Solid Tumor
Interventions
YL201Drug
Patients will be treated with YL201 intravenous (IV) infusion once every 3 weeks (Q3W) as a cycle.
YL201Drug
Patients will be treated with YL201 intravenous (IV) (A mg/kg or B g/kg infusion once every 3 weeks (Q3W) as a cycle.
YL201 and atezolizumabDrug
Patients will be treated with YL201 intravenous (IV) infusion (A mg/kg or B mg/kg, up to 200mg) followed by atezolizumab on day 1 of each 21 day cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate the occurrence of DLTs during the first cycle in Part 1Time frame: 21 days of Cycle 1
- Evaluate the AEs in Part 2 as characterized by type, frequency, severity, timing, seriousness and relationship to study treatmentTime frame: By the global end of trial date, approximately within 36 months
- Evaluate the prostate-specific antigen (PSA) response rate for patients with prostate cancer in Part 2Time frame: Approximately within 36 months
- Evaluate the objective response rate (ORR) for patients with solid tumors other than prostate cancer in Part 2, assessed using RECIST version 1.1Time frame: Approximately within 36 months
- Laboratory abnormalities as characterized by type, frequency, severity, and timing in Part 2Time frame: Biy the end of trial date, approximately within 36 months
- Incidence, nature, and severity of AEs graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) V5.0 in Part 3Time frame: Biy the end of trial date, approximately within 36 months
- Nature and frequency of dose-limiting toxicities (DLTs), incidence, nature, and severity of laboratory abnormalities in Part 3Time frame: At the end of cycle 1 (each cycle is 21 days)
Locations
45 sites in 6 countries. Site status is shown where the registry gives one.
002
Fair Oaks, California · Recruiting
001
La Jolla, California · Recruiting
003
Lone Tree, Colorado · Recruiting
004
Washington D.C., District of Columbia · Recruiting
005
Boston, Massachusetts · Recruiting
006
Ann Arbor, Michigan · Recruiting
007
Detroit, Michigan · Recruiting
008
St Louis, Missouri · Recruiting
009
Santa Fe, New Mexico · Recruiting
010
New York, New York · Recruiting
011
Chapel Hill, North Carolina · Recruiting
012
Nashville, Tennessee · Recruiting
014
Houston, Texas · Recruiting
015
Irving, Texas · Recruiting
013
San Antonio, Texas · Recruiting
016
Tyler, Texas · Recruiting
017
Fairfax, Virginia · Recruiting
018
Spokane, Washington · Recruiting
019
Tacoma, Washington · Recruiting
020
Edmonton, Alberta, Canada · Recruiting
021
Kelowna, British Columbia, Canada · Recruiting
022
Brampton, Ontario, Canada · Recruiting
023
Toronto, Ontario, Canada · Recruiting
024
Guangzhou, Guangdong, China · Completed
025
Zhengzhou, Henan, China · Completed
026
Bordeaux, France · Recruiting
027
Dijon, France · Recruiting
028
Marseille, France · Recruiting
029
Nantes, France · Not yet recruiting
030
Paris, France · Not yet recruiting
031
Poitiers, France · Recruiting
032
Saint-Herblain, France · Not yet recruiting
033
Suresnes, France · Recruiting
044
Otwock, Poland · Recruiting
045
Poznan, Poland · Not yet recruiting
034
Barcelona, Barcelona, Spain · Recruiting
035
Barcelona, Barcelona, Spain · Recruiting
039
Leganés, Madrid, Spain · Not yet recruiting
037
Madrid, Madrid, Spain · Recruiting
036
Madrid, Madrid, Spain · Recruiting
Showing 40 of 45 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.